(a)
(b)
(c)
(d)
(e)
(f)

Figure 1: Kaplan-Meier survival analysis of the time to PSA relapse (endpoint BCR: biochemical recurrence) in the RP patient cohort (n=536) for the PDE4D5, PDE4D7, and PDE4D9 scores. (a) Kaplan-Meier analysis of the BCR free survival of the PDE4D7 score in TMPRSS2-ERG positive tumours (n=280). (b) Kaplan-Meier analysis of the BCR free survival of the PDE4D7 score in TMPRSS2-ERG negative tumours (n=256). (c) Kaplan-Meier analysis of the BCR free survival of the PDE4D5 score in TMPRSS2-ERG positive tumours (n=280). (d) Kaplan-Meier analysis of the BCR free survival of the PDE4D5 score in TMPRSS2-ERG negative tumours (n=256). (e) Kaplan-Meier analysis of the BCR free survival of the PDE4D9 score in TMPRSS2-ERG positive tumours (n=280). (f) Kaplan-Meier analysis of the BCR free survival of the PDE4D9 score in TMPRSS2-ERG negative tumours (n=256). Censored patients are indicated by vertical bars. PDE4D5, PDE4D7, and PDE4D9 score categories were defined as PDE4D5/7/9 (1-2): PDE4D5/7/9 scores (1 to <2); PDE4D5/7/9 (2-3): PDE4D5/7/9 scores (2 to <3); PDE4D5/7/9 (3-4): PDE4D5/7/9 scores (3 to <4); PDE4D5/7/9 (4-5): PDE4D5/7/9 scores (4 to <=5).